RxDoctor Payments Data

John Bajgrowicz, MD

Cardiovascular Disease · Melrose Park, ILNPI 1245288331

Payments from drug & device makers

$8,570in general payments, 2019–2025

Across 404 payments — averaging $21.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Novartis$1K
  • Amgen$869
  • Boehringer Ingelheim$690
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$684
  • E.r. Squibb & Sons, L.L.C.$638
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$8,49499%
  • Education$761%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,570 in reported general payments places this provider in the 75th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$549,018
Medicare patients
1,172
Services billed
6,810

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban182$183,819
XareltoRivaroxaban49$66,027
Repatha SureclickEvolocumab43$32,418
Praluent PenAlirocumab21$15,107
EntrestoSacubitril/Valsartan13$14,423
Ranolazine ErRanolazine43$4,599
Metoprolol Succinate269$4,498
Carvedilol215$2,221
Losartan Potassium169$2,209
Flecainide Acetate47$2,173
Amlodipine Besylate248$2,139
Prasugrel Hcl36$2,004
Metoprolol Tartrate215$1,757
Ezetimibe64$1,566
Atorvastatin Calcium151$1,564

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$542$183,819182 claims
Johnson & JohnsonXarelto$1,354$66,02749 claims
NovartisEntresto$1,065$14,42313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Melrose Park

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →